XAV-939
Names
[ CAS No. ]:
284028-89-3
[ Name ]:
XAV-939
[Synonym ]:
3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one
2-[4-(Trifluoromethyl)phenyl]-1,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one
XAV939
XAV 939
4H-Thiopyrano[4,3-d]pyrimidin-4-one, 3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)phenyl]-
NVP-XAV 939
2-[4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-thiino[4,3-d]pyrimidin-4-ol
XAV-939
Biological Activity
[Description]:
[Related Catalog]:
[Target]
TNKS1:5 nM (IC50)
TNKS2:2 nM (IC50)
ARTD1:5500 nM (IC50)
ARTD2:479 nM (IC50)
[In Vitro]
[In Vivo]
[Kinase Assay]
[Cell Assay]
[Animal admin]
[References]
[Related Small Molecules]
Chemical & Physical Properties
[ Density]:
1.5±0.1 g/cm3
[ Boiling Point ]:
429.3ºC at 760 mmHg
[ Molecular Formula ]:
C14H11F3N2OS
[ Molecular Weight ]:
312.310
[ Flash Point ]:
213.4ºC
[ Exact Mass ]:
312.054413
[ PSA ]:
71.31000
[ LogP ]:
2.98
[ Appearance of Characters ]:
white to beige
[ Index of Refraction ]:
1.634
[ Storage condition ]:
Store at RT
[ Water Solubility ]:
DMSO: soluble5mg/mL, clear
MSDS
Safety Information
[ Symbol ]:
GHS06
[ Signal Word ]:
Danger
[ Hazard Statements ]:
H301-H319
[ Precautionary Statements ]:
P301 + P310-P305 + P351 + P338
[ Hazard Codes ]:
T
[ Risk Phrases ]:
R25;R36
[ Safety Phrases ]:
S26-S45
[ RIDADR ]:
UN 2811
[ Packaging Group ]:
III
Articles
PLoS ONE 9(10) , e111431, (2014)
Osteosarcoma (OS) is the most common type of solid bone cancer and remains the second leading cause of cancer-related death for children and young adults. Hypoxia is an element intrinsic to most solid...
XAV939 inhibits the stemness and migration of neuroblastoma cancer stem cells via repression of tankyrase 1.Int. J. Oncol. 45(1) , 121-8, (2014)
Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. One fundamental issue regarding NB recurrence and metastasis is the maintenance of cancer stem cells (CSCs) stemness. Tanky...
Targeting c-Met in melanoma: mechanism of resistance and efficacy of novel combinatorial inhibitor therapy.Cancer Biol. Ther. 15(9) , 1129-41, (2014)
Numerous tyrosine kinase inhibitors (TKIs) targeting c-Met are currently in clinical trials for several cancers. Their efficacy is limited due to the development of resistance. The present study aims ...